The epidemiology of the disease is strikingly concentrated in early childhood. Roughly 90 percent of pediatric cases present between the ages of 2 and 14, with a mean age of onset between 7.3 and 8.8 years. Clinicians classify morphea into several subtypes, including circumscribed plaque disease, linear morphea, generalized morphea, pansclerotic morphea, and mixed forms. Linear morphea is the most common subtype in children, and it is also among the most feared. When linear lesions cross the forehead and frontotemporal region, a presentation known as en coup de sabre, patients face a heightened risk of neurological involvement, facial asymmetry, and permanent deformity of the underlying skull and bone during critical growth windows. A related variant, Parry Romberg syndrome, can produce progressive hemifacial atrophy with or without visible skin hardening.

What makes morphea particularly dangerous in children is that it is not merely a skin disease. Approximately 20 percent of patients develop extracutaneous manifestations, including arthritis, uveitis, and neurological symptoms. Because the disease can scar actively growing bones and the developing skull, experts emphasize prompt and aggressive systemic treatment for deep or linear subtypes. Differentiating morphea from systemic sclerosis is also crucial: systemic sclerosis is characterized by sclerodactyly, Raynaud’s phenomenon, nail-fold capillary changes, telangiectasias, and internal organ involvement, features that generally distinguish it from the localized form. Interestingly, about half of morphea cases may undergo spontaneous resolution, complicating decisions about how intensively to treat.

The pathogenesis of morphea involves a complex interplay between genetic susceptibility, immune dysregulation, vascular injury, and aberrant fibrotic responses. Early lesions show a perivascular and interstitial inflammatory infiltrate of lymphocytes, macrophages, and plasma cells, accompanied by endothelial cell injury and microvascular dysfunction. Fibrosis itself is driven by persistent fibroblast activation and excessive deposition of type I and type III collagen. At the center of this process sits transforming growth factor-beta, or TGF-β, a master regulator that promotes fibroblast proliferation, drives differentiation into myofibroblasts, and boosts collagen synthesis while suppressing matrix degradation. Additional profibrotic mediators, including connective tissue growth factor, platelet-derived growth factor, and endothelin-1, amplify the fibrotic cascade.

Recent immunological insights have opened the door to precision therapies. A predominance of Th2-associated cytokines, particularly interleukin-4 and interleukin-13, promotes fibrosis through direct stimulation of fibroblast activity, and both cytokines signal through the Janus kinase-STAT pathway, especially STAT6. This provides a biological rationale for drugs targeting IL-4/IL-13 signaling, such as dupilumab, and for broader JAK-STAT inhibition. Even more dramatic was the discovery of novel gain-of-function STAT4 variants, inherited in an autosomal dominant manner or arising de novo, in children with disabling pansclerotic morphea, the most severe deep form of the disease. In a landmark study, four affected individuals from three families treated with oral ruxolitinib showed resolution of inflammatory biomarkers and clinical symptoms, with single-cell RNA sequencing revealing an immunodysregulatory signature that was effectively modulated by JAK inhibition.

For the majority of patients, treatment still follows a severity-based algorithm developed by the Childhood Arthritis and Rheumatology Research Alliance, or CARRA. Low-severity disease, defined as circumscribed superficial morphea without subcutaneous atrophy, extracutaneous involvement, or scalp hair loss, can be managed with high-potency topical corticosteroids, topical tacrolimus, calcipotriol, or imiquimod, often combined with phototherapy using broadband UVA, UVA1, or narrowband UVB. Tacrolimus ointment 0.1 percent demonstrated significant improvement in a randomized placebo-controlled trial after 12 weeks, while a case report of topical ruxolitinib cream 1.5 percent and another of the pan-JAK inhibitor delgocitinib in a 2-year-old suggest that topical JAK blockade may soon join the armamentarium. Imiquimod, an immune response modifier that induces interferon-gamma release and inhibits fibroblast collagen production, reduced lesion thickness in a prospective open-label study of nine children.

Moderate to severe disease demands systemic therapy, and methotrexate remains the undisputed first line. Dosing is calculated either by weight, at 0.3 to 0.6 mg/kg/week orally or up to 1 mg/kg/week subcutaneously, or by body surface area at 15 mg/m²/week, generally capped at 25 mg per week. Subcutaneous administration is often preferred for superior bioavailability and fewer gastrointestinal side effects. A systematic review found methotrexate effective in 93 percent of children, compared with 71 percent for phototherapy alone, and a randomized double-blind placebo-controlled trial showed that methotrexate combined with an initial prednisone course produced significantly better outcomes than placebo. Treatment is typically maintained for 12 to 24 months before tapering, and pulsed intravenous methylprednisolone may be added for severe or rapidly progressive cases, with side effects such as Cushingoid facies generally reversible after tapering.

For children who fail methotrexate, several alternatives have emerged. Mycophenolate mofetil achieved remission in 35 percent of patients within one year in a retrospective cohort, and in a separate study 90.9 percent of methotrexate-refractory children attained sustained remission over a mean follow-up of 9.4 years. Abatacept, which blocks T-cell costimulation, produced clinical improvement in 83 percent of eighteen refractory pediatric patients over 12 months, with some maintaining response to 24 months. Tocilizumab, an interleukin-6 receptor antagonist, significantly improved disease activity scores in five resistant patients after six months, though damage and quality-of-life measures did not change. Infliximab and the JAK inhibitors tofacitinib and baricitinib have each shown benefit in small case series, with tofacitinib reducing modified Localized Scleroderma Skin Activity Index and Damage Index scores without reported adverse effects.

The review’s authors caution that evidence for these emerging agents rests largely on case reports and small series, precluding definitive conclusions about comparative efficacy and long-term safety. Methotrexate and systemic corticosteroids remain the standard of care despite known risks including systemic toxicity and decreased bone density. Monitoring is especially critical in children, where corticosteroids can suppress growth velocity and bone mineral accretion. Objective assessment tools are improving: the Morphea Activity Measure correlates well with physician global assessments, and a novel multispectral imaging device using a handheld Antera 3D camera can predict new or enlarging lesions within three months with 90 percent sensitivity and 100 percent specificity, even in darkly pigmented skin. Ultrasound, magnetic resonance imaging, and 3D imaging add further objective windows into deep tissue involvement.

Finally, the review underscores that morphea is a whole-child disease. Although standardized quality-of-life instruments often show minimal impairment, qualitative studies of 690 pediatric patients across 13 studies reveal elevated stress, low self-worth, feelings of being different, and experiences of bullying tied to visible skin changes and treatment burden. The authors call for disease-specific psychosocial instruments, multidisciplinary care involving dermatology, rheumatology, physical therapy, psychology, and, for craniofacial disease, neurology, ophthalmology, and maxillofacial specialists, alongside standardized outcome metrics, robust disease registries, and personalized medicine approaches that tailor therapy to each child’s genetic and immunologic profile. As targeted therapies mature, the prospect of controlling fibrosis before it inflicts irreversible damage on growing bodies is moving steadily closer to reality.

Subject of Research: Advances in the diagnosis and treatment of pediatric morphea (localized scleroderma)

Article Title: Advances in the management of pediatric morphea: a narrative review

Article References: Kashyap, A., Jafari, A. J., Klimas, N., Koshelev, M., Mays, S. R., & Hebert, A. A. (2026). Advances in the management of pediatric morphea: a narrative review. Archives of Dermatological Research, 318(1), Article 448. https://doi.org/10.1007/s00403-026-04890-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04890-3

Keywords: pediatric morphea, localized scleroderma, autoimmune disease, methotrexate, JAK inhibitors, biologic therapy, fibrosis, STAT4, tocilizumab, abatacept, multidisciplinary care, skin disease

The numbers behind the warning are sobering. The overall incidence of checkpoint inhibitor-associated myocarditis ranges from 0.3 percent to 2.2 percent, with severe disease, graded 3 or higher on the Common Terminology Criteria for Adverse Events version 5.0, accounting for 0.15 percent to 0.69 percent of treated patients. Mortality remains stubbornly high at 37 to 50 percent, and combination immunotherapy is more dangerous than monotherapy, with reported death rates of 66 percent versus 44 percent. A Chinese cohort of 55,219 patients with advanced non-small cell lung cancer found an annual incidence of 0.51 percent for PD-1 inhibitor-associated myocarditis, or 5.1 cases per 1,000 person-years, underscoring that the threat scales with the enormous and growing global use of these drugs.

Combination regimens are a central theme of the new guidance. A French nationwide database analysis showed that the six-month cumulative incidence of myocarditis reached 1.6 percent for PD-1 plus CTLA-4 inhibitor combinations, compared with 0.2 to 0.4 percent for monotherapy. In a large retrospective cohort of 53,018 patients, combination therapy carried a hazard ratio of 2.92 for myocarditis relative to monotherapy. Pharmacovigilance data drawn from 171,132 case reports in the United States Food and Drug Administration safety database identified 1,326 myocarditis cases across nine checkpoint inhibitors, with a reporting odds ratio of 30.1 overall, and the signal for PD-L1 plus CTLA-4 combination therapy was more than double that of PD-L1 monotherapy. The 2026 recommendations also extend their scope to newer agents, including the PD-1/CTLA-4 bispecific antibodies cadonilimab and iparomlimab/tuvonralimab, the PD-1/VEGF bispecific antibody ivonescimab, and other novel constructs now approved in China, reflecting emerging evidence on cardiac injury linked to bispecific antibodies.

Among the most striking updates is the formal incorporation of thymic imaging into risk stratification. Patients with thymic epithelial tumors, particularly thymoma, face dramatically elevated risk: one analysis found an odds ratio of 32 for myocarditis in thymoma patients, while a meta-analysis showed myocarditis rates of 29 percent in thymoma versus 2 percent in thymic carcinoma. These patients also develop myocarditis earlier, with a median time to onset of 21 days compared with 41 days for other cancers, and suffer more life-threatening arrhythmias, more concomitant myositis and myasthenia gravis-like syndromes, and higher 30-day mortality. A multicenter study established a thymic grading system based on chest computed tomography, finding that a pretreatment thymic grade of 3 or higher, indicating a solid component above 50 percent, was far more common in patients who went on to develop myocarditis, with an odds ratio of 25. Acetylcholine receptor antibody positivity, a marker of thymus-associated autoimmunity, was also significantly more frequent in affected patients and predicted early cardiotoxic events.

The recommendations therefore advise that before starting checkpoint inhibitors, all patients undergo baseline evaluation including family and personal history, biomarkers of myocardial injury, electrocardiography and echocardiography. For patients with a history of thymic tumors or suspected thymic abnormalities, chest CT is recommended to assess thymic size, morphology and density, along with acetylcholine receptor antibody testing when autoimmune thymic disease is suspected. Those with residual thymic tissue, abnormal ovoid thymic morphology or abnormal mediastinal fat attenuation should be evaluated by a multidisciplinary cardio-oncology team to weigh the benefit-risk ratio and design individualized monitoring. Coexisting autoimmune disease is not an absolute contraindication to immunotherapy, but the panel recommends assessing disease activity first, coordinating with rheumatology, and keeping baseline immunosuppression at the lowest effective dose, ideally no more than 10 milligrams per day of prednisone equivalent. Routine prophylactic glucocorticoids to prevent immune-related adverse events are explicitly not recommended, because baseline immunosuppression has been associated with shorter survival and higher relapse of underlying autoimmune disease.

Once therapy begins, the guidance prescribes an intensive early monitoring schedule built around the observation that most myocarditis cases strike within the first three months, with median time to onset of 28 to 65 days across studies. For patients treated every two weeks, symptom assessment, electrocardiography and cardiac troponin testing are recommended before cycles 2 through 9; for three-week schedules, before cycles 2 through 6. Biomarker data show why vigilance matters: in hospitalized patients, cardiac troponin T was elevated in 98 percent, troponin I in 88 percent and creatine kinase in 75 percent, and troponin T proved the most sensitive early marker, remaining elevated for months while other markers normalized faster. Baseline troponin T at twice the upper reference limit carried a hazard ratio of 31.71 for subsequent myocarditis in one prospective cohort. Electrocardiographic changes also carry prognostic weight, with new QRS widening beyond 110 milliseconds associated with a more than threefold increase in major adverse cardiac events.

Diagnosis follows a hierarchical framework anchored either by histopathology or by clinical criteria. Endomyocardial biopsy remains the gold standard, revealing multifocal inflammatory infiltration dominated by CD8-positive T lymphocytes with significant cardiomyocyte loss, but the panel individualizes its use given sampling error and procedural risk. Without biopsy, diagnosis requires elevated troponin, preferably troponin T, plus either one major criterion, cardiac magnetic resonance findings meeting the modified Lake Louise criteria with evidence of myocardial edema on T2 mapping and non-ischemic injury on T1 mapping, or at least two minor criteria such as a compatible clinical syndrome, ventricular arrhythmias or conduction abnormalities, reduced left ventricular function, concurrent immune-related adverse events like myositis or myasthenia gravis, or partially concordant cardiac magnetic resonance findings. The panel cautions that conventional cardiac magnetic resonance has limited early sensitivity: late gadolinium enhancement was detected in only 48 percent of cases overall and just 21.6 percent within four days of admission, so quantitative T1 and T2 mapping and, in selected cases, positron emission tomography with tracers such as 18F-FDG, 68Ga-DOTATOC or 68Ga-FAPI can provide complementary information. Differential diagnosis must exclude infectious myocarditis, acute coronary syndrome, Takotsubo cardiomyopathy, pulmonary embolism and tumor progression, with coronary angiography reserved for ST-elevation patterns.

Treatment hinges on speed and severity stratification. Once myocarditis is confirmed, checkpoint inhibitor therapy is stopped immediately and glucocorticoids started, ideally within 24 hours of symptom onset; a multicenter study of 126 patients showed that steroids begun within 24 hours significantly reduced peak troponin compared with later initiation, and high-dose regimens of 501 to 1,000 milligrams per day of methylprednisolone were associated with a major adverse cardiac event rate of 22 percent versus 54.6 to 61.9 percent with lower doses. Occult subclinical injury warrants observation or modest prednisone dosing, mild disease calls for 1 to 2 milligrams per kilogram per day of methylprednisolone, severe disease requires 500-milligram pulse therapy plus intravenous immunoglobulin at 0.4 grams per kilogram daily, and critical disease demands intensive care, 500 to 1,000 milligram daily pulses, immunoglobulin, immediate second-line immunosuppression and life support including temporary pacing, plasma exchange and mechanical circulatory support. Steroid resistance, defined by failure of troponin to fall by at least half or persistence of conduction block, arrhythmias or ventricular dysfunction after three days, triggers escalation to agents such as abatacept, antithymocyte globulin, mycophenolate mofetil, tacrolimus, the JAK inhibitors tofacitinib and ruxolitinib, or biologics including tocilizumab and alemtuzumab, with infliximab used cautiously given signals of increased cardiovascular death. Notably, a prospective strategy combining high-dose abatacept with ruxolitinib and glucocorticoids cut mortality to 3 percent versus 60 percent with high-dose steroids alone, and randomized trials including ATRIUM and ACHLYS are now testing abatacept as initial therapy.

Recovery does not end the story. The panel recommends weekly monitoring of symptoms, electrocardiography and troponin during steroid tapering over roughly four to six weeks, followed by visits every two to three weeks for three months after discontinuation, since troponin T can remain elevated for months and late cardiac events still occur. Resumption of immunotherapy is reserved for fully resolved, biologically recovered disease, defined as normalized troponin T and complete steroid withdrawal, and is generally limited to patients with occult or mild initial episodes; severe or critical myocarditis mandates permanent discontinuation. When rechallenge is unavoidable and no alternatives exist, the decision should be made jointly by cardiology and oncology, with de-escalation from combination therapy to PD-1 or PD-L1 monotherapy and intensified biomarker surveillance, acknowledging that roughly a third to half of rechallenged patients experience recurrent immune-related adverse events. Looking ahead, the guidelines highlight artificial intelligence-assisted early screening, machine learning risk scores integrating baseline characteristics and treatment regimens, and multimodal imaging analytics as promising tools to catch this elusive, fast-moving complication before it becomes fatal, while emphasizing that multidisciplinary cardio-oncology collaboration remains the backbone of safe immunotherapy.

Subject of Research: Clinical diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis

Article Title: Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-associated myocarditis (2026 edition)

Article References: Yan, W., Qingqing, C., Yuan, L., Jiahui, C., Hao, L., Jinyi, L., Zhiming, W., Yinman, W., Zhifeng, Y., Shilong, Z., Lingying, M., Ji, Z., Shufu, C., Chi, Z., Rongle, L., Xin, Z., Cong, W., Xianling, Q., Zheng, L., … Junbo, G. (2026). Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-associated myocarditis (2026 edition). Clinical Cancer Bulletin, 5(1), Article 13. https://doi.org/10.1007/s44272-026-00065-3

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00065-3

Keywords: immune checkpoint inhibitors, myocarditis, cardio-oncology, immunotherapy toxicity, glucocorticoids, abatacept, cardiac troponin, thymoma, cardiac magnetic resonance, bispecific antibodies, immunosuppression, clinical guidelines